Roche Submits Application For FDA Approval Of Actemra For The Treatment Of Rheumatoid Arthritis
Actemra is the first humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody seeking approval to treat rheumatoid arthritis Roche announced the submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for Actemra (tocilizumab) to reduce the signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA).”The filing for Actemra in the U.S. [click link for full article]

Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay
Title: Arimidex Beats Tamoxifen in Keeping Breast Cancer at Bay
Category: Health News
Created: 12/15/2007 2:00:00 AM
Last Editorial Review: 12/17/2007